Quick Answer
LISATA THERAPEUTICS, INC. reported Operating Income Loss of -$18.21 million for the year ending 2025.
- LISATA THERAPEUTICS, INC. showed an increase of +18.7% in Operating Income Loss from 2024 to 2025.
- This data is from LISATA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), LISATA THERAPEUTICS, INC.'s Operating Income Loss has grown by 3.5%.
- Historical annual values: Fiscal year 2025: -$18.21 million | Fiscal year 2024: -$22.41 million | Fiscal year 2023: -$25.71 million | Fiscal year 2022: -$57.60 million | Fiscal year 2021: -$29.05 million | Fiscal year 2020: -$19.15 million | Fiscal year 2019: -$20.09 million | Fiscal year 2018: -$16.99 million | Fiscal year 2017: -$27.59 million | Fiscal year 2016: -$29.50 million | Fiscal year 2015: -$113.85 million | Fiscal year 2014: -$57.74 million | Fiscal year 2013: -$36.81 million | Fiscal year 2012: -$30.39 million | Fiscal year 2011: -$34.00 million | Fiscal year 2010: -$18.88 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: